Globally, with the trend of aging and the change of disease spectrum, the number of cancer deaths per year exceeds 10million. This makes the scientific progress of cancer diagnosis and treatment more and more attention.
mission bio focuses on molecular diagnosis and genomic precision medicine at high throughput single cell level. In recent years, with the development of targeted treatment, precision medical technology, cancer diagnosis and treatment has gradually become the focus of the academic and industry, and is favored by various venture capital funds.
“mission bio is entering the track of early cancer diagnosis, which is suitable for the two trends and directions of cancer diagnosis in the future,” fusion, the company’s earliest investor and calendar investor Zhang Lu, founder and managing partner of fund, said: “first, the application of microfluidic technology in the direction of single cell sequencing, and microfluidic technology itself is an innovation at the level of medical devices, which can pull cancer diagnosis to a smaller and more accurate dimension.
the second is the direction of bioinformatics related to single cell sequencing. At present, we are in a stage of digital transformation of medical treatment. All our physiological data are very valuable and can be used to better assist the diagnosis and monitoring of medical treatment. Mission bio has sequenced the data of information biology and microfluidic technology as early as 2015. Finally, it provides personalized diagnosis results by integrating the data analysis results. ”
tapestri platform can use the integrated technology of single cell multi-layer histology developed by mission bio to optimize the clinical experiment of cancer targeted treatment, and can accurately detect the heterogeneity of disease progress and treatment response. The application areas include blood cancer, solid tumor and genome editing validation. The platform includes instruments, consumables and analysis software, which integrates seamlessly with the existing ngs workflow.
it is worth emphasizing that tapestri can detect DNA and protein changes in a single cell, which is important for assessing the effectiveness of targeted therapy – because in large-scale analysis, such as large-scale analysis of different types of cells, the effects of other uncontrolled variables can be eliminated. This breakthrough technology enables researchers and clinicians to analyze tens of thousands of individual cells in parallel, 50 times more sensitive than traditional ngs technologies; their single base resolution is several orders of magnitude higher than that of other single cell DNA methods.
for the recognition of the technology, mission bio has become the only single cell sequencing company invited to participate in the gene editing seminar sponsored by the National Institute of standards and technology of the United States, providing quality control scheme for CRISPR gene editing.
the company said that the financing fund of this round will be used to expand tapestri platform platform, expand its application scope in clinical trials of new cancer treatment, and better analyze and display the effect and characteristics of cell and gene therapy.
“the exit direction of most medical device companies is to withdraw through merger and acquisition. But mission bio is not only for a specific disease, but for all small cell carcinoma, which is equivalent to a platform effect. So the possibility of future exit is much greater than that of a general medical device company. ” Zhang Lu said. Before the foundation of fusion fund, Zhang Lu also successfully founded a medical device company, which was acquired by Listed Companies in the United States.
it is worth mentioning that apart from helping optimize clinical trials for blood cancer and tumor treatment programs, mission bio’s technology can also be used to validate gene editing. In recent years, clinical application based on CRISPR gene editing technology has attracted much attention, and gene editing market has great potential in the future. Focus